Wenzel Spine has received FDA clearance for its expandable sacroiliac (SI) fusion implant, panaSIa.
This marks the first FDA-cleared expandable implant for SI joint fusion, offering a new treatment option for patients with sacroiliac joint dysfunction.
The panaSIa SI Fusion System expands Wenzel Spine’s portfolio of stand-alone, expandable devices, built on over 17 years of experience in implant design.
This system enables minimally invasive dorsal placement with a streamlined surgical approach. Its expandable design stabilizes the SI joint, allows for post-expansion graft delivery, and provides immediate fixation, key to reducing micro-motion and enhancing early pain relief.
The implant is designed to reduce recovery time, minimize surgical complications, and deliver long-term relief for patients.
It is available in two sizes, allowing surgeons to match the implant to individual patient anatomy.
With FDA clearance of panaSIa, Wenzel Spine advances minimally invasive spinal care, offering a first-in-class expandable SI fusion option in a growing therapeutic area.
